The Daily Star – Reuters
An experimental Alzheimer’s disease drug from Eisai (4523.T) and Biogen (BIIB.O) slowed cognitive decline in a closely watched trial but may carry a risk of dangerous side effects for certain patients, according to new data presented on Tuesday. Read more on The Daily Star
